AGIO Agios Pharmaceuticals, Inc. stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 6, 2026Agios Pharmaceuticals, Inc. (AGIO) closed at $29.41 (+4.03%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 38, RS Rating 22, -36.1% from its 52-week high, +7.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
AGIO technical analysis
Trend
AGIO's moving averages are mixed — no clean uptrend or downtrend. It closed 11.7% below the 50-day ($33.27) and 7.5% below the 200-day ($31.76). ADX(14) at 25 points to a moderate trend. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 38, in the bearish half of its range. MACD crossed below its signal line 4 sessions ago. Its RS Rating of 22 puts its weighted 12-month performance ahead of about 22% of the US market.
Volume and volatility
Volume on the latest session ran 1.6× its 20-day average. It trades about $44.7M a day on average. ATR(14) is $1.98, 6.7% of price — its typical daily range.
Key levels
The chart pattern's support is $29.74 and its resistance $37.03. The 52-week range is $22.24 to $46.00; price is 36.1% below the high and 32.1% above the low. The VWAP anchored at the 52-week high is $30.26, above price.
Performance
AGIO returned -3.8% (1 week), -8.0% (1 month), -9.8% (3 months), +5.7% (6 months), -27.5% (1 year), +7.9% (year to date).
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Pharmaceutical Preparations · Listed 2013 · 540 employees
Congress activity
Disclosed STOCK Act trades in AGIO · 4 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Gilbert Cisneros house · D · CA · traded 2026-08-20 | Buy | $1K–$15K | 2026-08-20 | 2026-09-10 | |
Gilbert Cisneros house · CA · traded 2026-03-03 | Buy | $1K–$15K | 2026-03-03 | 2026-04-06 | |
Gilbert Cisneros house · D · CA · traded 2025-04-17 | Buy | $1K–$15K | 2025-04-17 | 2025-05-06 | |
Gilbert Cisneros house · D · CA · traded 2025-01-29 | Buy | $1K–$15K | 2025-01-29 | 2025-02-11 |
Insider activity
SEC Form 4 transactions in AGIO · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Gheuens Sarah Chief Medical Officer · Common stock · 2026-10-26 | Exercise | 7.87K | $197K | 2026-10-26 | 2026-10-28 |
Gheuens Sarah Chief Medical Officer · Common stock · 2026-10-26 | Sell | 7.87K | $296K | 2026-10-26 | 2026-10-28 |
Gheuens Sarah Chief Medical Officer · Stock options (right to buy) · 2026-10-26 | Exercise | 7.87K | — | 2026-10-26 | 2026-10-28 |
Gheuens Sarah Chief Medical Officer · Common stock · 2026-08-04 | Sell | 30K | $914K | 2026-08-04 | 2026-08-06 |
Backstrom Jay T. Director · Common stock · 2026-07-08 | Grant | 1.45K | — | 2026-07-08 | 2026-07-10 |
Backstrom Jay T. Director · Restricted stock units · 2026-07-08 | Exercise | 1.45K | — | 2026-07-08 | 2026-07-10 |
CAPELLO JEFFREY D Director · Common stock · 2026-06-13 | Exercise | 1.98K | — | 2026-06-13 | 2026-06-16 |
CAPELLO JEFFREY D Director · Restricted stock units · 2026-06-13 | Exercise | 1.98K | — | 2026-06-13 | 2026-06-16 |
Owen Adams Catherine Director · Common stock · 2026-06-13 | Exercise | 1.98K | — | 2026-06-13 | 2026-06-16 |
Owen Adams Catherine Director · Restricted stock units · 2026-06-13 | Exercise | 1.98K | — | 2026-06-13 | 2026-06-16 |
SEC filings
EDGAR filings in AGIO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.